Paul Hartmann AG buy Covacoro
Start price
20.02.18
/
50%
€370.00
Target price
22.10.18
€420.00
Performance (%)
-4.59%
End price
22.10.18
€346.00
Summary
This prediction ended on 22.10.18 with a price of €346.00. With a performance of -4.59%, the BUY prediction for Paul Hartmann AG by Covacoro closed slightly in the red. Covacoro has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Paul Hartmann AG | 2.500% | 2.500% | -2.844% | -46.475% |
| iShares Core DAX® | -0.051% | 4.829% | 17.062% | 18.811% |
| iShares Nasdaq 100 | 1.659% | 2.417% | 38.705% | 56.555% |
| iShares Nikkei 225® | 0.658% | -2.173% | 13.159% | 7.768% |
| iShares S&P 500 | 0.964% | 2.547% | 30.492% | 47.355% |
According to Covacoro what are the pros and cons of Paul Hartmann AG for the foreseeable future?
Pros
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
Some uniques
Known brand
Could be very worthwhile Investment >20% year
Future proof or reliable business model
Cons
Comments by Covacoro for this prediction
In the thread Paul Hartmann AG diskutieren
Covacoro stimmt der fundamentalen Bewertung mit dem Ergebnis 'unterbewertet' zu
Covacoro stimmt am 20.02.2018 der fundamentalen Bewertung mit dem Ergebnis unterbewertet zu.
Konservative Medtech Aktie für Langfristanleger.
(Vom Mitglied beendet)
Stopped prediction by Covacoro for Paul Hartmann AG
Paul Hartmann AG
Start price
Target price
Perf. (%)
€360.00
14.07.21
14.07.21
€450.00
14.07.22
14.07.22
0.28%
24.07.21
24.07.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
Paul Hartmann AG
Start price
Target price
Perf. (%)
€353.00
30.06.21
30.06.21
€400.00
30.06.22
30.06.22
3.40%
10.07.21
10.07.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth